文献速递骨质疏松与钙磷/甲状旁腺

G蛋白α11亚基结构域界面激活突变导致常染色体显性低钙血症2型

Activating Mutations of the G-protein Subunit α 11 Interdomain Interface Cause Autosomal Dominant Hypocalcemia Type 2.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

研究在2个常染色体显性低钙血症(ADH)家系中发现2个新型Gα11杂合种系变异p.Gly66Ser和p.Arg149His,位于Gα11螺旋域与GTP酶域界面;体外实验显示变异导致钙感应受体信号通路的增益功能,NPS 2143可使其恢复正常。

要点

  • 在2个ADH家系中未发现CaSR变异,发现2个新型Gα11杂合变异p.Gly66Ser和p.Arg149His。
  • 两个变异位于Gα11螺旋域与GTP酶域界面,该区域涉及鸟嘌呤核苷酸结合。
  • 表达Ser66或His149变异Gα11的细胞在低细胞外钙时反应与野生型相似,高钙刺激下Ca2+i和MAPK反应呈剂量依赖性显著增加。

核心结论

  • 研究发现2个导致ADH2的新型Gα11增益功能突变,提示Gα11结构域界面是增益功能突变的热点区域。

研究设计与样本

  • 研究纳入2个常染色体显性低钙血症家系,对CaSR和Gα11基因进行变异筛查。
  • 将野生型和变异表达构建体瞬时转染至稳定表达CaSR的HEK293细胞(HEK-CaSR),检测细胞外钙刺激后的细胞内钙和MAPK反应。

主要发现

  • 未发现CaSR变异,发现2个新型杂合种系Gα11变异p.Gly66Ser和p.Arg149His。
  • 同源建模显示Gly66和Arg149残基位于Gα11螺旋域与GTP酶域界面,该界面参与鸟嘌呤核苷酸结合,也是其他3个已报道ADH2突变的位点。
  • 表达Ser66或His149变异Gα11蛋白的细胞在低细胞外钙时Ca2+i和MAPK反应与野生型细胞相似,但在细胞外钙刺激后呈剂量依赖性显著增加。
  • 用CaSR负向变构调节剂NPS 2143处理表达Ser66和His149变异Gα11的细胞,可使Ca2+i和MAPK反应正常化。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Autosomal dominant hypocalcemia types 1 and 2 (ADH1 and ADH2) are caused by germline gain-of-function mutations of the calcium-sensing receptor (CaSR) and its signaling partner, the G-protein subunit α 11 (Gα 11), respectively. More than 70 different gain-of-function CaSR mutations, but only 6 different gain-of-function Gα 11 mutations are reported to date. METHODS: We ascertained 2 additional ADH families and investigated them for CaSR and Gα 11 mutations. The effects of identified variants on CaSR signaling were evaluated by transiently transfecting wild-type (WT) and variant expression constructs into HEK293 cells stably expressing CaSR (HEK-CaSR), and measuring intracellular calcium (Ca2+i) and MAPK responses following stimulation with extracellular calcium (Ca2+e). RESULTS: CaSR variants were not found, but 2 novel heterozygous germline Gα 11 variants, p.Gly66Ser and p.Arg149His, were identified. Homology modeling of these revealed that the Gly66 and Arg149 residues are located at the interface between the Gα 11 helical and GTPase domains, which is involved in guanine nucleotide binding, and this is the site of 3 other reported ADH2 mutations. The Ca2+i and MAPK responses of cells expressing the variant Ser66 or His149 Gα 11 proteins were similar to WT cells at low Ca2+e, but significantly increased in a dose-dependent manner following Ca2+e stimulation, thereby indicating that the p.Gly66Ser and p.Arg149His variants represent pathogenic gain-of-function Gα 11 mutations. Treatment of Ser66- and His149-Gα 11 expressing cells with the CaSR negative allosteric modulator NPS 2143 normalized Ca2+i and MAPK responses. CONCLUSION: Two novel ADH2-causing mutations that highlight the Gα 11 interdomain interface as a hotspot for gain-of-function Gα 11 mutations have been identified.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Gorvin CM, Stokes VJ, Boon H, et al. Activating Mutations of the G-protein Subunit α 11 Interdomain Interface Cause Autosomal Dominant Hypocalcemia Type 2. J Clin Endocrinol Metab. 2020. PMID: 31820785. doi:10.1210/clinem/dgz251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。